Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting

Inclusion Criteria: * Patients must be aged less than 76 years at the time of diagnosis * Patients must have had a baseline serum PSA level measured before starting any treatment and within six months of diagnosis * Patients must have been diagnosed between 1990 and 2006 with a clinically localized (clinical stage T1-T3, N0 or NX, MO or MX) prostate cancer, in the judgment of the treating physician * The initial diagnostic biopsy sample must be available for review. Patients should have (but are not required to have) tissue blocks available for review. * There must be no evidence of metastatic disease * While data collection will include review of the reports of any imaging studies of the prostate, bones, or soft tissues, these studies are not essential * Each patient should have had an adequate medical evaluation to document the status of disease for the first five years after diagnosis. Follow-up should include an annual PSA and digital rectal examination. Records will be reviewed to seek all information about medical evaluation after the time of diagnosis. Exclusion Criteria: * Patients older than 76 years at the time of diagnosis * Patients who have not had a baseline serum PSA level measured before starting any treatment * Patients who do not have the initial diagnosis biopsy sample for review * Patients with evidence of metastatic disease